List view / Grid view
renal cell carcinoma (RCC)
Lenvima and Keytruda has demonstrated positive top-line results in a Phase III trial in patients with advanced renal cell carcinoma.
The majority of patients eligible for cancer immunotherapy drugs known as checkpoint inhibitors received treatment within a few months of FDA approval, according to a new Yale-led study.
The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending cabozantinib for some kidney cancer patients
12 January 2017 | By Niamh Marriott, Digital Editor
Everolimus (Afinitor, Novartis) is now recommended to be available on the NHS as a treatment option for some patients with advanced renal cell carcinoma...
25 July 2016 | By Niamh Louise Marriott, Digital Content Producer
Ipsen announced that CHMP & EMA have provided a positive opinion for Cabometyx for the treatment of advanced renal cell carcinoma (RCC) in adults...
8 July 2016 | By Victoria White, Digital Content Producer
The S-TRAC study of Sutent versus placebo in the adjuvant setting met its primary endpoint of improving disease-free survival in renal cell carcinoma...